• Je něco špatně v tomto záznamu ?

A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging

G. Arendash, C. Cao, H. Abulaban, R. Baranowski, G. Wisniewski, L. Becerra, R. Andel, X. Lin, X. Zhang, D. Wittwer, J. Moulton, J. Arrington, A. Smith,

. 2019 ; 71 (1) : 57-82. [pub] -

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028948

BACKGROUND: Small aggregates (oligomers) of the toxic proteins amyloid-β (Aβ) and phospho-tau (p-tau) are essential contributors to Alzheimer's disease (AD). In mouse models for AD or human AD brain extracts, Transcranial Electromagnetic Treatment (TEMT) disaggregates both Aβ and p-tau oligomers, and induces brain mitochondrial enhancement. These apparent "disease-modifying" actions of TEMT both prevent and reverse memory impairment in AD transgenic mice. OBJECTIVE: To evaluate the safety and initial clinical efficacy of TEMT against AD, a comprehensive open-label clinical trial was performed. METHODS: Eight mild/moderate AD patients were treated with TEMT in-home by their caregivers for 2 months utilizing a unique head device. TEMT was given for two 1-hour periods each day, with subjects primarily evaluated at baseline, end-of-treatment, and 2 weeks following treatment completion. RESULTS: No deleterious behavioral effects, discomfort, or physiologic changes resulted from 2 months of TEMT, as well as no evidence of tumor or microhemorrhage induction. TEMT induced clinically important and statistically significant improvements in ADAS-cog, as well as in the Rey AVLT. TEMT also produced increases in cerebrospinal fluid (CSF) levels of soluble Aβ1-40 and Aβ1-42, cognition-related changes in CSF oligomeric Aβ, a decreased CSF p-tau/Aβ1-42 ratio, and reduced levels of oligomeric Aβ in plasma. Pre- versus post-treatment FDG-PET brain scans revealed stable cerebral glucose utilization, with several subjects exhibiting enhanced glucose utilization. Evaluation of diffusion tensor imaging (fractional anisotropy) scans in individual subjects provided support for TEMT-induced increases in functional connectivity within the cognitively-important cingulate cortex/cingulum. CONCLUSION: TEMT administration to AD subjects appears to be safe, while providing cognitive enhancement, changes to CSF/blood AD markers, and evidence of stable/enhanced brain connectivity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028948
003      
CZ-PrNML
005      
20210114155356.0
007      
ta
008      
210105s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/JAD-190367 $2 doi
035    __
$a (PubMed)31403948
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Arendash, Gary $u NeuroEM Therapeutics, Inc., Phoenix, AZ, USA.
245    12
$a A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging / $c G. Arendash, C. Cao, H. Abulaban, R. Baranowski, G. Wisniewski, L. Becerra, R. Andel, X. Lin, X. Zhang, D. Wittwer, J. Moulton, J. Arrington, A. Smith,
520    9_
$a BACKGROUND: Small aggregates (oligomers) of the toxic proteins amyloid-β (Aβ) and phospho-tau (p-tau) are essential contributors to Alzheimer's disease (AD). In mouse models for AD or human AD brain extracts, Transcranial Electromagnetic Treatment (TEMT) disaggregates both Aβ and p-tau oligomers, and induces brain mitochondrial enhancement. These apparent "disease-modifying" actions of TEMT both prevent and reverse memory impairment in AD transgenic mice. OBJECTIVE: To evaluate the safety and initial clinical efficacy of TEMT against AD, a comprehensive open-label clinical trial was performed. METHODS: Eight mild/moderate AD patients were treated with TEMT in-home by their caregivers for 2 months utilizing a unique head device. TEMT was given for two 1-hour periods each day, with subjects primarily evaluated at baseline, end-of-treatment, and 2 weeks following treatment completion. RESULTS: No deleterious behavioral effects, discomfort, or physiologic changes resulted from 2 months of TEMT, as well as no evidence of tumor or microhemorrhage induction. TEMT induced clinically important and statistically significant improvements in ADAS-cog, as well as in the Rey AVLT. TEMT also produced increases in cerebrospinal fluid (CSF) levels of soluble Aβ1-40 and Aβ1-42, cognition-related changes in CSF oligomeric Aβ, a decreased CSF p-tau/Aβ1-42 ratio, and reduced levels of oligomeric Aβ in plasma. Pre- versus post-treatment FDG-PET brain scans revealed stable cerebral glucose utilization, with several subjects exhibiting enhanced glucose utilization. Evaluation of diffusion tensor imaging (fractional anisotropy) scans in individual subjects provided support for TEMT-induced increases in functional connectivity within the cognitively-important cingulate cortex/cingulum. CONCLUSION: TEMT administration to AD subjects appears to be safe, while providing cognitive enhancement, changes to CSF/blood AD markers, and evidence of stable/enhanced brain connectivity.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a Alzheimerova nemoc $x diagnostické zobrazování $x metabolismus $x psychologie $x terapie $7 D000544
650    _2
$a amyloidní beta-protein $x krev $x mozkomíšní mok $7 D016229
650    _2
$a kognice $7 D003071
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neurozobrazování $7 D059906
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a transkraniální magnetická stimulace $x škodlivé účinky $x metody $7 D050781
650    _2
$a výsledek terapie $7 D016896
650    _2
$a proteiny tau $x krev $x mozkomíšní mok $7 D016875
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cao, Chuanhai $u College of Pharmacy, University of South Florida, Tampa, FL, USA.
700    1_
$a Abulaban, Haitham $u University of South Florida Health/Byrd Alzheimer's Institute, Tampa, FL, USA.
700    1_
$a Baranowski, Rob $u Left Coast Engineering, Escondido, CA, USA.
700    1_
$a Wisniewski, Gary $u Invicro, Boston, MA, USA.
700    1_
$a Becerra, Lino $u Invicro, Boston, MA, USA.
700    1_
$a Andel, Ross $u School of Aging Studies, University of South Florida, Tampa, FL, USA. Department of Neurology, 2nd Faculty of Medicine, Charles University/Motol University Hospital, Prague, Czech Republic.
700    1_
$a Lin, Xiaoyang $u College of Pharmacy, University of South Florida, Tampa, FL, USA.
700    1_
$a Zhang, Xiaolin $u College of Pharmacy, University of South Florida, Tampa, FL, USA.
700    1_
$a Wittwer, David $u Ocotillo Electromagnetics, Inc., Chandler, AZ, USA.
700    1_
$a Moulton, Jay $u RF Exposure Laboratory, San Marcos, CA, USA.
700    1_
$a Arrington, John $u University Diagnostic Institute, Tampa, FL, USA.
700    1_
$a Smith, Amanda $u University of South Florida Health/Byrd Alzheimer's Institute, Tampa, FL, USA.
773    0_
$w MED00006350 $t Journal of Alzheimer's disease : JAD $x 1875-8908 $g Roč. 71, č. 1 (2019), s. 57-82
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31403948 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155354 $b ABA008
999    __
$a ok $b bmc $g 1609283 $s 1120128
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 71 $c 1 $d 57-82 $e - $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace